Supplementary Materials

This PDF file includes:

  • Fig. S1. B cell gating strategy.
  • Fig. S2. The major transcriptional checkpoint occurs at the transitional T3 B cell stage in human versus the FO B cell stage in mouse.
  • Fig. S3. Transitional and FO human B cells analyzed by flow cytometry demonstrate comparable B cell surface protein amounts despite differences in forward and side scatter.
  • Fig. S4. Patients identified with activating mutations in PIK3CD.
  • Fig. S5. The PIK3CD M61V mutation promotes BCR-stimulated AKT and S6 activation.
  • Fig. S6. FO B cell development is blocked in patients with gain-of-function PIK3CD (PI3Kδ) mutations.
  • Fig. S7. APDS naïve (IgD+CD27) B cells cluster unique from healthy controls by scRNA-seq analysis using t-SNE.
  • Fig. S8. cAMP signaling is similar between early transitional and late transitional/FO B cells.
  • Fig. S9. Adenosine is sufficient to inhibit pS6 activation in transitional T3 and FO B cells.
  • Fig. S10. Increased abundance of cell surface ectonucleotidases at the FO B cell stage is not conserved between human and mouse.
  • Fig. S11. B cell viability in vitro.
  • Table S1. Top gene set enrichment pathways for transitional to FO B cell development.
  • Table S2. Characteristics of patients with APDS.
  • Table S3. Primers used for generating the WT, E1021K, and M61V mutant PI3Kδ constructs.

[Download PDF]